Kelly Erikson

Kelly Erikson

Auto-generated profile, based on publicly available information

Kelly Erikson

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
FGFrederico Omar Gleber-Netto
Frederico Omar Gleber-Netto
XRXiayu Rao
Xiayu Rao
TGTheresa Guo
Theresa Guo
YXYuanxin Xi
Yuanxin Xi
MGMeng Gao
Meng Gao
CPCurtis Pickering
Curtis Pickering
Incidence of HPV + oropharyngeal squamous cell carcinoma (OPSCC) has been increasing dramatically. Although long-term survival rates for these patients are high, they often suffer from permanent radiotherapy-related morbidity. This has prompted the development of de-escalation clinical protocols to reduce morbidity. However, a subset of patients do not respond even to standard therapy and have poor outcomes. It is unclear how to properly identify and treat the high- and low-risk HPV + OPSCC patients. Since HPV positivity drives radiotherapy sensitivity, we hypothesized that variations in HPV biology may cause differences in treatment response and outcome. By analyzing gene expression data, we identified variations in HPV-related molecules among HPV + OPSCC. A subset of tumors presented a molecular profile distinct from that of typical HPV + tumors and exhibited poor treatment response, indicating molecular and clinical similarities with HPV – tumors. These molecular changes were also observed in vitro and correlated with radiation sensitivity. Finally, we developed a prognostic biomarker signature for identification of this subgroup of HPV + OPSCC and validated it in independent cohorts of oropharyngeal and cervical carcinomas. These findings could translate to improved patient stratification for treatment deintensification and new therapeutic approaches for treatment-resistant HPV-related cancer.

11 July 2022 in Neoplasia
Verified
Journal Article
Open access
CMChieko Michikawa
Chieko Michikawa
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
AHAmani M. Harrandah
Amani M. Harrandah
TKTatiana V Karpinets
Tatiana V Karpinets
RGRekha Rani Garg
Rekha Rani Garg
NSNatalie Silver
Natalie Silver
Recently, increased number of studies have demonstrated a relationship between the oral microbiome and development of head and neck cancer, however, there are few studies to investigate the role of oral bacteria in the context of the tumor microenvironment in a single head and neck subsite. Here, paired tumor and adjacent normal tissues from thirty-seven oral tongue squamous cell carcinoma (SCC) patients were subjected to 16S rRNA gene sequencing and whole exome sequencing (WES), in addition to RNA sequencing for tumor samples. We observed that Fusobacterium was significantly enriched in oral tongue cancer and that Rothia and Streptococcus were enriched in adjacent normal tissues. A decrease in alpha diversity was found in tumor when compared to adjacent normal tissues. While increased Fusobacterium in tumor samples was not associated with changes in immune cell infiltration, it was associated with increased PD-L1 mRNA expression. Therefore, we examined the effects of Fusobacterium on PD-L1 expression in head and neck SCC cell lines. We demonstrated that infection with Fusobacterium species can increase both PD-L1 mRNA and surface PD-L1 protein expression on head and neck cancer cell lines. The correlation between Fusobacterium and PD-L1 expression in oral tongue SCC, in conjunction with the ability of the bacterium to induce PD-L1 expression in vitro suggests a potential role for Fusobacterium on modulation of the tumor immune microenvironment in head and neck cancer.

3 December 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
BUBurak Uzunparmak
Burak Uzunparmak
MGMeng Gao
Meng Gao
ALAntje Lindemann
Antje Lindemann
KEKelly Erikson
Kelly Erikson
LWLi Wang
Li Wang
CPCurtis Pickering
Curtis Pickering
Caspase-8 ( CASP8 ) is one of the most frequently mutated genes in head and neck squamous carcinomas (HNSCCs), and CASP8 mutations are associated with poor survival. The distribution of these mutations in HNSCCs suggests that they are likely to be inactivating. Inhibition of CASP8 has been reported to sensitize cancer cells to necroptosis, a regulated cell death mechanism. Here, we show that knockdown of CASP8 renders HNSCCs susceptible to necroptosis by a second mitochondria-derived activator of caspase (SMAC) mimetic, birinapant, in combination with pan-caspase inhibitors Z-VAD-FMK or emricasan and radiation. In a syngeneic mouse model of oral cancer, birinapant, particularly when combined with radiation, delayed tumor growth and enhanced survival under CASP8 loss. Exploration of molecular underpinnings of necroptosis sensitivity confirmed that the level of functional receptor-interacting serine/threonine protein kinase 3 (RIP3) determines susceptibility to this mode of death. Although an in vitro screen revealed that low RIP3 levels rendered many HNSCC cell lines resistant to necroptosis, patient tumors maintained RIP3 expression and should therefore remain sensitive. Collectively, these results suggest that targeting the necroptosis pathway with SMAC mimetics, especially in combination with radiation, may be relevant therapeutically in HNSCC with compromised CASP8 status, provided that RIP3 function is maintained.

1 July 2018 in Cell Systems
Verified
Journal Article
Closed access
IAIsmael Al-Ramahi
Ismael Al-Ramahi
BLBoxun Lu
Boxun Lu
SPSimone Di Paola
Simone Di Paola
KPKaifang Pang
Kaifang Pang
MHMaria de Haro
Maria de Haro
JBJuan Botas
Juan Botas

6 May 2021 in Small GTPases
Verified
Journal Article
Open access
JDJoseph G. Duman
Joseph G. Duman
FBFrancisco A. Blanco
Francisco A. Blanco
CCChristopher A. Cronkite
Christopher A. Cronkite
QRQin Ru
Qin Ru
KEKelly C. Erikson
Kelly C. Erikson
KTKimberley F. Tolias
Kimberley F. Tolias
Synaptic connections between neurons are essential for every facet of human cognition and are thus regulated with extreme precision. Rho-family GTPases, molecular switches that cycle between an active GTP-bound state and an inactive GDP-bound state, comprise a critical feature of synaptic regulation. Rho-GTPases are exquisitely controlled by an extensive suite of activators (GEFs) and inhibitors (GAPs and GDIs) and interact with many different signalling pathways to fulfill their roles in orchestrating the development, maintenance, and plasticity of excitatory synapses of the central nervous system. Among the mechanisms that control Rho-GTPase activity and signalling are cell surface receptors, GEF/GAP complexes that tightly regulate single Rho-GTPase dynamics, GEF/GAP and GEF/GEF functional complexes that coordinate multiple Rho-family GTPase activities, effector positive feedback loops, and mutual antagonism of opposing Rho-GTPase pathways. These complex regulatory mechanisms are employed by the cells of the nervous system in almost every step of development, and prominently figure into the processes of synaptic plasticity that underlie learning and memory. Finally, misregulation of Rho-GTPases plays critical roles in responses to neuronal injury, such as traumatic brain injury and neuropathic pain, and in neurodevelopmental and neurodegenerative disorders, including intellectual disability, autism spectrum disorder, schizophrenia, and Alzheimer’s Disease. Thus, decoding the mechanisms of Rho-GTPase regulation and function at excitatory synapses has great potential for combatting many of the biggest current challenges in mental health.

28 April 2011 in Gene
Verified
Journal Article
Closed access
AMAlbert Mulenga
Albert Mulenga
KEKelly Erikson
Kelly Erikson